Read time: 1 minute

UPDATE: NIH Says Trial Data May Give Incomplete View Of AstraZeneca Vaccine

The company said the panel found “no increased risk of thrombosis or events characterized by thrombosis" among the 21,583 participants receiving at least one dose of the vaccine

UPDATE:


*********************

The Covid-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in preventing symptomatic illness in a large trial in the US, Chile and Peru, the company said today, paving the way for U.S. approval and yet another supply stream for a usable vaccine. Via The Guardian:

The vaccine was 100% effective against severe or critical disease and hospitalisation and was safe, the drugmaker said on Monday, releasing results of the late-stage human trial study of more than 32,000 volunteers across all age groups.

The data will give credence to the British vaccine after results from earlier, separate late-stage studies raised questions about the robustness of the data.

[...] AstraZeneca said an independent safety committee conducted a specific review of the blood clots in the US trial, as well as cerebral venous sinus thrombosis (CVST), which is an extremely rare blood clot in the brain, with the help of an independent neurologist.

The London-listed company said the panel found “no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no events in this trial”.

Can you help us out?

For 16 years we have been exposing Washington lies and untangling media deceit. We work 7 days a week, 16 hours a day for our labor of love, but with rising hosting and associated costs, we need your help! Could you donate $21 for 2021? Please consider a one-time or recurring donation of whatever amount you can spare, or consider subscribing for an ad-free experience. It will be greatly appreciated and help us continue our mission of exposing the real FAKE NEWS!

More C&L Coverage

Discussion

New Commenting System

Our comments are now powered by Insticator. In order to comment you will need to create an Insticator account. The process is quick and simple. Please note that the ability to comment with a C&L site account is no longer available.

We welcome relevant, respectful comments. Any comments that are sexist or in any other way deemed hateful by our staff will be deleted and constitute grounds for a ban from posting on the site. Please refer to our Terms of Service (revised 3/17/2016) for information on our posting policy.

Please Do Not Use the Login Link at the Top of the Site.

In order to comment you must use an Insticator account. To register an account, enter your comment and click the post button. A dialog will then appear allowing you create your account.

We will be retiring our Crooks and Liars user account system in January, 2021.

Thank you.
C&L Team